Scilex Subsidiary Sells ACEA Pharma for $1B in Phoenix Shares, Gains 82% Stake in Nasdaq-Bound Entity
summarizeSummary
Scilex Holding Company's indirect subsidiary, ACEA Therapeutics, Inc., and its wholly-owned subsidiary, ACEA Pharma, Inc., have entered a definitive agreement to sell 100% of ACEA Pharma to Phoenix Asia Holdings Limited (PHOE). In exchange, ACEA Thera will receive 100,000,000 newly-issued ordinary shares of Phoenix, valued at $1 billion. Upon closing, Phoenix will be renamed ACEA Pharma, Inc., and its common stock is expected to be listed on Nasdaq, with ACEA Thera anticipating an approximately 82% ownership stake in the Go-Forward Company. This transformative transaction follows recent disclosures of a $120 million investment by Scilex in Datavault AI and a proposed 15% increase in its equity incentive plan. Critically, Scilex's last 10-K (April 10, 2026) expressed substantial doubt about its ability to continue as a going concern, citing increased net losses and revenue decline. This $1 billion deal, where Scilex's subsidiary retains an 82% stake in a newly public entity, is highly material and could significantly address the company's "going concern" issues and dramatically reshape its financial position and strategic focus. Traders will monitor the closing of the acquisition, expected by the end of Q2 2026, and the subsequent Nasdaq listing of the renamed Phoenix entity.
At the time of this announcement, SCLX was trading at $11.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $97.6M. The 52-week trading range was $3.92 to $34.27. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: GlobeNewswire.